Event Participants
Executives
2 Krishna Kanumuri, Siva Chittor
Analysts
10 Akshay Kaila, Amey Chalke, Binay Singh, Dhaval, Karan Gupta, Rajat Baldeva, Sajal Kapoor, Siddharth Meghandi, Tirumala Reddy, Yaseer Lakhdawala
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Total Revenue | ₹553 crores | YoY +12% vs ₹496 crores prior year; in line with expectations, H2 expected stronger |
| CRO Revenue | ~40% of revenue | YoY +26%, driven by discovery chemistry scaling and integrated service delivery for ~65% of discovery customers |
| CDMO Revenue | ~60% of revenue | YoY +6% on lumpy delivery schedule; supported by 33 active commercial molecules and 14 late-phase molecules |
| Commercial Molecules | 33 | Stable base; 3 of the 4 new commercial contracts already added in Q1 |
| Late-Phase Molecules | 14 | 6 added over last 15 months; 5 via large pharma FTE engagements |
| Repeat Revenue | >90% (FY25 & FY26) | Reflects customer retention and deepening engagement; supports de-risked growth |
| FDA-Approved Molecules (CY2025) | 5 | Sai contributed to discovery, development, or commercial manufacturing |
| Launches Supported (5 years) | 17 | Includes launch-quantity supply capability |
| FY27 CapEx Guidance | ₹1,100–1,300 crores | Maintained; includes greenfield site, peptide, and formulation capacity |
Geographic & Segment Commentary
CRO (Discovery): Grew 26% YoY, contributing ~40% of revenue. Discovery chemistry services continue to scale, with a pilot collaboration converted into a long-term, high-volume partnership during Q1. Approximately 65% of discovery customers now use integrated service delivery (primarily biotech), and management hopes to transition at least two large pharma customers to the integrated model this year.
CDMO (Development & Manufacturing): Grew 6% YoY, contributing ~60% of revenue. Pipeline stands at 33 active commercial molecules and 14 late-phase molecules, with 6 late-phase additions over the last 15 months, 5 of which came through large pharma FTE engagements. Negotiations are underway for a second large pharma FTE process development engagement, expected to close by end Q2 with work commencing in Q3.
Offshore Presences (Boston/Manchester): Boston is a stronger P&L contributor, with discovery revenue growing at a CAGR of ~20–25% since late 2020. Both act as satellite centers that cultivate customer relationships early and feed work back to India, functioning as one integrated team with India operations.
Company-Specific & Strategic Commentary
Multi-Modality Expansion: Dedicated peptide development lab for a top-tier pharma company coming online shortly; greenfield peptide manufacturing facility near Hyderabad expected operational in 2028 (total peptide spend <₹300 crores). XDC center of excellence opening for payloads, linkers, and conjugation across antibodies, peptides, PROTACs, and oligonucleotides. Formulation capability (Phase 1 oral solids) ~6 months from operational readiness, driven by China-plus-one demand from existing development relationships.
Advanced Process Technology: Successfully scaled up a late-stage API intermediate using flow chemistry for a large pharma customer; developing continuous downstream operations (extraction, distillation, crystallization) targeting flow applications in commercial manufacturing.
Scientific Collaboration: Published joint paper with AstraZeneca on reaction kinetics determination early in development; ADC bio-conjugation characterization capabilities published in high-impact peer-reviewed journals, reinforcing scientific depth.
Talent & Sustainability: Campus recruitment program kickstarted led by a former board member; structured management development programs and intensified Sai Academy capability-building. Secured EcoVadis Platinum rating (top 1% of companies assessed) for sustainability performance.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue Growth | 15–20% (mid-term, 3–5 years) | Management confident; FY26 actual growth ~30% demonstrates upside; H2 FY27 expected stronger than H1 |
| EBITDA Margin | 28–30% | Retained guidance; driven by integrated model and science-led positioning |
| H2 vs H1 Skew | Stronger H2 (FY27) | Capacity additions (Bidar first 225 KL block, discovery) going live Q2/Q3 |
| FY27 CapEx | ₹1,100–1,300 crores | Includes greenfield site, peptide, formulations; financial flexibility retained |
| New Large Pharma FTE | Close by end Q2, work from Q3 | Process development engagement under negotiation |
| Phase 3 Regulatory Milestones | 2 this FY, 1 in Q2 FY28 | Pipeline progression; one approval received in FY26 |
Risks & Constraints
| Risk | Context |
|---|---|
| Business Lumpiness | Quarterly revenue is volatile due to delivery/PO timing; FY26 H1/H2 was ~48/52 vs historical 40/60. Management guides on a mid-term basis to smooth this and encourages evaluating longer-term trends. |
| Capacity Fill Risk | Discovery capacity sold out faster than expected in Q1; Bidar blocks coming online Q2/Q3. If demand softens, management uses a modular, just-in-time CapEx approach to slow additions. |
| Phase 3 Timeline Slip | Two regulatory milestones expected this FY and one in Q2 FY28; approval timing can slip and impact CDMO ramp, given only late-phase and commercial molecules are tracked for probability of success. |
| Formulation Margin Risk | Commercial oral solids typically carry lower profitability; entry is limited to Phase 1 clinical supply initially, tied to existing China-plus-one development relationships, reducing standalone margin pressure. |
| India Sourcing Trend Reversal | Geopolitical and IP-driven China-plus-one diversification is currently strong; a shift in pharma sourcing strategy could temper CRO growth assumptions over the medium term. |
Q&A Highlights
FTE & Big Pharma Engagement Acceleration
- Question: Has the shift toward integrated CRDMO relationships, FTEs, and IP-related diversification accelerated this calendar year, or is it a continuation? (Binay Singh, Morgan Stanley)
- Answer: Customers are building 5-year relationships, starting small and growing big; acceleration in scale and scope is visible. FTE model started 15 months ago, with one customer already end-to-end from discovery to commercial. India is now seeing the migration of the "middle part" of the value chain (FTE development) that historically went to Chinese CDMOs. (Krishna Kanumuri, Siva Chittor)
H1/H2 Revenue Skew
- Question: Is FY27 H2 skew heavier than usual because more capacity comes online this year? (Binay Singh, Morgan Stanley)
- Answer: Correct. FY26 was unusual at ~48/52 H1/H2 split vs the historical ~40/60 pattern; management proactively flagged this shift on the prior call. (Siva Chittor)
Discovery Chemistry Conversion
- Question: What drove the large customer conversion in CRO chemistry, and how big can this become? (Amey Chalke, JM Financial)
- Answer: Not just one customer - multiple customers are expanding. Growth comes from both scale in line services (discovery chemistry) and value-chain integrated services, with some converts happening more linearly and others going more integrated. (Krishna Kanumuri)
New Commercial Molecule Ramp
- Question: Can you clarify modalities, primary vs secondary supplier status, and revenue per product for the 4 new commercial contracts this year? (Amey Chalke, JM Financial)
- Answer: Three of the four are commercial supplies, likely primary in 2 of 3 (anecdotal). Three are decently sized value products consistent with top commercial products; one is a lower-volume product. (Siva Chittor)
Formulations & China-Plus-One Strategy
- Question: Why enter oral solids given typically lower profitability in commercial formulations? (Amey Chalke, JM Financial)
- Answer: Only Phase 1 clinical supply is being built initially, driven by customer demand and the China-plus-one strategy. It only works well when an existing development relationship exists, not standalone. (Krishna Kanumuri)
FTE Retention Probability & Wallet Share
- Question: Does engaging via dedicated FTE development materially increase the probability of retaining molecules commercially, and does integration change revenue per customer? (Sajal Kapoor, Antifragile Thinking)
- Answer: The stated intent of pharma partners is to keep programs with Sai through full product life cycle; only a capacity mismatch would trigger re-evaluation. With >90% revenue from existing customers while growing ~30%, the objective is to increase wallet share and diversify services, which also de-risks revenue concentration within customers. (Krishna Kanumuri, Siva Chittor)
CapEx Hurdle Rates & Deferral
- Question: What internal return thresholds are used before committing to 1,300 crores of CapEx, and what would cause you to slow down? (Sajal Kapoor, Antifragile Thinking)
- Answer: Hurdle rates are set above company ROCE/ROE targets. Capability-building investments (peptides, XDC) are harder to defer once committed; capacity additions are evaluated and slowed when demand signals soften, using a modular, just-in-time approach. (Siva Chittor)
AI vs High-Throughput Experimentation & Capacity Timeline
- Question: Is the high-throughput experimentation platform the AI initiative, and is capacity expansion on schedule? (Siddharth Meghandi, CWC)
- Answer: HTE and AI are distinct; AI focuses on eliminating non-value-add work, document generation, and literature-assisted processes. Capacity: discovery facility came on stream in Q1 and is already sold out; Bidar first 225 KL block on track for Q2/Q3; formulation capacity 6 months away. (Siva Chittor)
Peptide Platform Scope
- Question: Is the peptide capability build focused on GLP-1 first, or both GLP-1 and PDCs? (Siddharth Meghandi, CWC)
- Answer: Peptides go beyond GLP-1 - recent blockbuster launches (Merck's PTHP9 for cholesterol, J&J's oral peptide for psoriasis) and PDCs are expanding the pipeline. Building broad-based peptide capabilities across the therapeutic window, discovery to commercial. (Krishna Kanumuri)
Guidance Conservatism & Lumpiness
- Question: Why is guidance constrained at 15–20% when the pipeline is strong, given Q1/Q2 growth slowdown? (Karan Gupta, Ashika Stock Broking)
- Answer: Guidance is mid-term (3–5 years); FY26 grew ~30% on an annualized basis. Quarter-to-quarter revenue is lumpy due to delivery timing; the business should be evaluated on a longer-term trend. Management aims to meet and beat guidance. (Krishna Kanumuri)
Offshore Facilities Contribution
- Question: How are Boston and Manchester shaping up commercially? (Siddharth Meghandi, CWC)
- Answer: Boston is a better contributor to P&L; both act as satellite centers that cultivate customers early and feed India operations. Discovery has grown at a CAGR of ~20–25% since Boston's establishment in late 2020. (Siva Chittor)
Key Takeaway
Sai Life Sciences Q1 FY27 revenue grew 12% YoY to ₹553 crores, with CRO at +26% (40% of revenue) and CDMO at +6% (60% of revenue), matching expectations. Management maintained mid-term revenue guidance of 15–20% with EBITDA margins of 28–30%, expecting H2 to be stronger as Bidar capacity and discovery capacity go live. Strategic focus is multi-modality expansion - dedicated peptide development lab, XDC center of excellence, Phase 1 oral solids formulations, and flow chemistry scale-up - while deepening FTE engagements with 19 of the top 25 pharma companies. Pipeline stands at 33 commercial molecules and 14 late-phase candidates, with 6 late-phase additions over 15 months and 5 via FTE deals. FY27 CapEx guidance of ₹1,100–1,300 crores funds greenfield, peptide, and formulation capacity. Watch points: quarterly lumpiness, Phase 3 regulatory milestones (2 this FY, 1 in Q2 FY28), the second large pharma FTE closure by end Q2, and discovery capacity fill rates.